Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus

Human Gene Therapy

Volumn 20, Issue 9, 2009, Pages 975-988

  Doronin, Konstantin ^a   Shashkova, Elena V ^a   May, Shannon M ^a   Hofherr, Sean E ^a   Barry, Michael A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERGOCALCIFEROL; MACROGOL; N [(]4 METHOXYPHENYLACETYL[)]DEHYDROALANINE; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; WARFARIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; GENE DELIVERY SYSTEM; GENETIC TRANSDUCTION; HEPATITIS; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER TOXICITY; METASTASIS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROSTATE CARCINOMA; VIRUS PARTICLE; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CARCINOMA; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; LUCIFERASES; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 68649104639     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.028     Document Type: Article

References (61)

1. Alemany, R. (2007). Cancer selective adenoviruses. Mol. Aspects Med. 28, 42-58.
2. Alemany, R., Suzuki, K., and Curiel, D.T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605-2609.
3. Barton, K.N., Paielli, D., Zhang, Y., Koul, S., Brown, S.L., Lu, M., Seely, J., Kim, J.H., and Freytag, S.O. (2006). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater ef-ficacy without increased toxicity. Mol. Ther. 13, 347-356.
4. Carlisle, R.C., Di, Y., Cerny, A.M., Sonnen, A.F., Sim, R.B., Green, N.K., Subr, V., Ulbrich, K., Gilbert, R.J., Fisher, K.D., Finberg, R.W., and Seymour, L.W. (2009).Human erythro-cytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909-1918.
5. Cascallo, M., Alonso, M.M., Rojas, J.J., Perez-Gimenez, A., Fueyo, J., and Alemany, R. (2007). Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adeno-virus based on the pRB pathway. Mol. Ther. 15, 1607-1615.
6. Cattaneo, R., Miest, T., Shashkova, E.V., and Barry, M.A. (2008). Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat. Rev. Microbiol. 6, 529-540.
7. Croyle, M.A., Chirmule, N., Zhang, Y., and Wilson, J.M. (2001). "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792-4801.
8. Croyle, M.A., Le, H.T., Linse, K.D., Cerullo, V., Toietta, G., Beaudet, A., and Pastore, L. (2005). PEGylated helper-dependent denoviral vectors: Highly efficient vectors with an enhanced safety profile. Gene Ther. 12, 579-587.
9. Dhar, D., Spencer, J.F., Toth, K., and Wold, W.S. (2009). Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immuno-suppressed Syrian hamsters. J. Virol. 83, 2130-2139.
10. Di Paolo, N.C., van Rooijen, N., and Shayakhmetov, D.M. (2009). Redundant and synergistic mechanisms control the sequestration of blood-borne adenovirus in the liver. Mol. Ther. 17, 675-684.
11. Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A.E., and Wold, W.S. (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147-6155.
12. Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A.E., Krajcsi, P., Krougliak, V., and Wold, W.S. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75, 3314-3324.
13. Doronin, K., Toth, K., Kuppuswamy, M., Krajcsi, P., Tollefson, A.E., and Wold, W.S. (2003). Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378-387.
14. Duncan, S.J., Gordon, F.C., Gregory, D.W., McPhie, J.L., Post-lethwaite, R., White, R., and Willcox, H.N. (1978). Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40, 45-61.
15. Fishburn, C.S. (2008). The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 7, 4167-4183.
16. Gao, J.Q., Eto, Y., Yoshioka, Y., Sekiguchi, F., Kurachi, S., Mor-ishige, T., Yao, X., Watanabe, H., Asavatanabodee, R., Sakurai, F., Mizuguchi, H., Okada, Y., Mukai, Y., Tsutsumi, Y., Mayumi, T., Okada, N., and Nakagawa, S. (2007). Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J. Control. Release 122, 102-110.
17. Garber, K. (2006). China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298-300.
18. Harris, J.M., and Chess, R.B. (2003). Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221.
19. Heideman, D.A., Steenbergen, R.D., van Der, T.J., Scheffner, M., Alemany, R., Gerritsen, W.R., Meijer, C.J., Snijders, P.J., and van Beusechem, V.W. (2005). Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol. her. 12, 1083-1090.
20. Hermiston, T. (2006). A demand for next-generation oncolytic adenoviruses. Curr. Opin. Mol. Ther. 8, 322-330.
21. Hofherr, S.E., Shashkova, E.V., Weaver, E.A., Khare, R., and Barry, M.A. (2008). Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16, 1276-1282.
22. Jakubczak, J.L., Ryan, P., Gorziglia, M., Clarke, L., Hawkins, L.K., Hay, C., Huang, Y., Kaloss, M., Marinov, A., Phipps, S., Pinkstaff, A., Shirley, P., Skripchenko, Y., Stewart, D., Forry-Schaudies, S., and Hallenbeck, P.L. (2003). An oncolytic ade-novirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: Dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 63, 1490-1499.
23. Kalyuzhniy, O., Di Paolo, N.C., Silvestry, M., Hofherr, S.E., Barry, M.A., Stewart, P.L., and Shayakhmetov, D.M. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 5483-5488.
24. Kirn, D. (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 8, 89-98.
25. Kojaoghlanian, T., Flomenberg, P., and Horwitz, M.S. (2003). The impact of adenovirus infection on the immunocompro-mised host. Rev. Med. Virol. 13, 155-171.
26. Kreppel, F., and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide. Mol. Ther. 16, 16-29.
27. Liu, Q., Zaiss, A.K., Colarusso, P., Patel, K., Haljan, G., Wick-ham, T.J., and Muruve, D.A. (2003). The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum. Gene Ther. 14, 627-643.
28. Liu, T.C., Galanis, E., and Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117.
29. Liu, T.C., Thorne, S.H., and Kirn, D.H. (2008). Oncolytic ade-noviruses for cancer gene therapy. Methods Mol. Biol. 433, 243-258.
30. Lohr, F., Huang, Q., Hu, K., Dewhirst, M.W., and Li, C.Y. (2001). Systemic vector leakage and transgene expression by in-tratumorally injected recombinant adenovirus vectors. Clin. Cancer Res. 7, 3625-3628.
31. Luo, J., Xia, Q., Zhang, R., Lv, C., Zhang, W., Wang, Y., Cui, Q., Liu, L., Cai, R., and Qian, C. (2008). Treatment of cancer with a novel dual-targeted conditionally replicative adenovi-rus armed with mda-7=IL-24 gene. Clin. Cancer Res. 14, 2450-2457.
32. Mok, H., Palmer, D.J., Ng, P., and Barry, M.A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11, 66-79.
33. Morrison, J., Briggs, S.S., Green, N., Fisher, K., Subr, V., Ulbrich, K., Kehoe, S., and Seymour, L.W. (2008). Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther. 16, 244-251.
34. Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., and Kirn, D. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 8, 746-759.
35. O'Riordan, C.R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S.C., Smith, A.E., and Francis, G.E. (1999). PE-Gylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10, 1349-1358.
36. Ogawara, K., Rots, M.G., Kok, R.J., Moorlag, H.E., van Loenen, A.M., Meijer, D.K., Haisma, H.J., and Molema, G. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 15, 433-443.
37. Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., Kemball-Cook, G., Ni, S., Lieber, A., McVey, J.H., Nicklin, S.A., and Baker, A.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561.
38. Post, D.E., Sandberg, E.M., Kyle, M.M., Devi, N.S., Brat, D.J., Xu, Z., Tighiouart, M., and van Meir, E.G. (2007). Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 67, 6872-6881.
39. Reid, T., Warren, R., and Kirn, D. (2002). Intravascular adeno-viral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther. 9, 979-986.
40. Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M., and Brayden, D.J. (2008). Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin. Drug Deliv. 5, 371-383.
41. Sarkar, D., Su, Z.Z., Vozhilla, N., Park, E.S., Gupta, P., and Fisher, P.B. (2005). Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc. Natl. Acad. Sci. U.S.A. 102, 14034-14039.
42. Sauthoff, H., Hu, J., Maca, C., Goldman, M., Heitner, S., Yee, H., Pipiya, T., Rom, W.N., and Hay, J.G. (2003). Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points. Hum. Gene Ther. 14, 425-433.
43. Schepelmann, S., Ogilvie, L.M., Hedley, D., Friedlos, F., Martin, J., Scanlon, I., Chen, P., Marais, R., and Springer, C.J. (2007). Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxy-peptidase G2. Cancer Res. 67, 4949-4955.
44. Shashkova, E.V., Spencer, J.F., Wold, W.S., and Doronin, K. (2007). Targeting interferon-a increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced on-colytic adenovirus. Mol. Ther. 15, 598-607.
45. Shashkova, E.V., Doronin, K., Senac, J.S., and Barry, M.A. 2008a). Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res. 68, 5896-5904.
46. Shashkova, E.V., Kuppuswamy, M.N., Wold, W.S., and Dor-onin, K. (2008b). Anticancer activity of oncolytic adenovirus vector armed with IFN-a and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15, 61-72.
47. Shayakhmetov, D.M., Eberly, A.M., Li, Z.Y., and Lieber, A. (2005). Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J. Virol. 79, 1053-1061.
48. Small, E.J., Carducci, M.A., Burke, J.M., Rodriguez, R., Fong, L., Van Ummersen, L., Yu, D.C., Aimi, J., Ando, D., Working, P., Kirn, D., and Wilding, G. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14, 107-117.
49. Snoeys, J., Lievens, J., Wisse, E., Jacobs, F., Duimel, H., Collen, D., Frederik, P., and de Geest, B. (2007). Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther. 14, 604-612.
50. Sova, P., Ren, X.W., Ni, S., Bernt, K.M., Mi, J., Kiviat, N., and Lieber, A. (2004). A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 9, 496-509.
51. Su, C., Peng, L., Sham, J., Wang, X., Zhang, Q., Chua, D., Liu, C., Cui, Z., Xue, H., Wu, H., Yang, Q., Zhang, B., Liu, X., Wu, M., and Qian, Q. (2006). Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-g gene yields efficient antitumor activity in immunodefi-cient and immunocompetent mice. Mol. Ther. 13, 918-927.
52. Tollefson, A.E., Scaria, A., Hermiston, T.W., Ryerse, J.S., Wold, L.J., and Wold, W.S. (1996). The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296-2306.
53. Tollefson, A.E., Kuppuswamy, M., Shashkova, E.V., Doronin, K., and Wold, W.S. (2007). Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol. Med. 130, 223-235.
54. Toth, K., Spencer, J.F., Dhar, D., Sagartz, J.E., Buller, R.M., Painter, G.R., and Wold, W.S. (2008). Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad. Sci. U.S.A. 105, 7293-7297.
55. Waddington, S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., Pink, R., Buckley, S.M., Greig, J.A., Denby, L., Custers, J., Morita, T., Francischetti, I.M., Monteiro, R.Q., Barouch, D.H., van Rooijen, N., Napoli, C., Havenga, M.J., Nicklin, S.A., and Baker, A.H. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409.
56. Wang, Y., Wang, H., Li, C.Y., and Yuan, F. (2006). Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery. Mol. Cancer Ther. 5, 362-366.
57. Weaver, E.A., and Barry, M.A. (2008). Effects of shielding ade-noviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 19, 1369-1382.
58. Wisse, E., Jacobs, F., Topal, B., Frederik, P., and de Geest, B. (2008). The size of endothelial fenestrae in human liver sinu- soids: Implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193-1199.
59. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R.G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37-44.
60. Wortmann, A., Vohringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., Kochanek, S., and Kreppel, F. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154-162.
61. Yu, W., and Fang, H. (2007). Clinical trials with oncolytic ade-novirus in China. Curr. Cancer Drug Targets 7, 141-148.